Berry Genomics Co Ltd (000710) - Net Assets
Based on the latest financial reports, Berry Genomics Co Ltd (000710) has net assets worth CN¥1.65 Billion CNY (≈ $241.34 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.34 Billion ≈ $342.96 Million USD) and total liabilities (CN¥694.43 Million ≈ $101.62 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 000710 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.65 Billion |
| % of Total Assets | 70.37% |
| Annual Growth Rate | 13.44% |
| 5-Year Change | -29.2% |
| 10-Year Change | 1357.37% |
| Growth Volatility | 228.56 |
Berry Genomics Co Ltd - Net Assets Trend (1994–2024)
This chart illustrates how Berry Genomics Co Ltd's net assets have evolved over time, based on quarterly financial data. See Berry Genomics Co Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Berry Genomics Co Ltd (1994–2024)
The table below shows the annual net assets of Berry Genomics Co Ltd from 1994 to 2024. For live valuation and market cap data, see 000710 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.72 Billion ≈ $250.98 Million |
-9.47% |
| 2023-12-31 | CN¥1.89 Billion ≈ $277.24 Million |
-18.66% |
| 2022-12-31 | CN¥2.33 Billion ≈ $340.85 Million |
-7.70% |
| 2021-12-31 | CN¥2.52 Billion ≈ $369.30 Million |
+4.18% |
| 2020-12-31 | CN¥2.42 Billion ≈ $354.48 Million |
+3.21% |
| 2019-12-31 | CN¥2.35 Billion ≈ $343.45 Million |
+20.84% |
| 2018-12-31 | CN¥1.94 Billion ≈ $284.22 Million |
+24.47% |
| 2017-12-31 | CN¥1.56 Billion ≈ $228.34 Million |
+1267.92% |
| 2016-12-31 | CN¥114.08 Million ≈ $16.69 Million |
-3.07% |
| 2015-12-31 | CN¥117.69 Million ≈ $17.22 Million |
-9.49% |
| 2014-12-31 | CN¥130.03 Million ≈ $19.03 Million |
+7.46% |
| 2013-12-31 | CN¥121.00 Million ≈ $17.71 Million |
-2.17% |
| 2012-12-31 | CN¥123.68 Million ≈ $18.10 Million |
+0.96% |
| 2011-12-31 | CN¥122.50 Million ≈ $17.93 Million |
+0.23% |
| 2010-12-31 | CN¥122.22 Million ≈ $17.89 Million |
+6.74% |
| 2009-12-31 | CN¥114.51 Million ≈ $16.76 Million |
+9.74% |
| 2008-12-31 | CN¥104.34 Million ≈ $15.27 Million |
+10.41% |
| 2007-12-31 | CN¥94.51 Million ≈ $13.83 Million |
-5.29% |
| 2006-12-31 | CN¥99.78 Million ≈ $14.60 Million |
+1.21% |
| 2005-12-31 | CN¥98.59 Million ≈ $14.43 Million |
-12.56% |
| 2004-12-31 | CN¥112.75 Million ≈ $16.50 Million |
+0.57% |
| 2003-12-31 | CN¥112.11 Million ≈ $16.41 Million |
+2.97% |
| 2002-12-31 | CN¥108.87 Million ≈ $15.93 Million |
-32.58% |
| 2001-12-31 | CN¥161.48 Million ≈ $23.63 Million |
-22.01% |
| 2000-12-31 | CN¥207.06 Million ≈ $30.30 Million |
-6.27% |
| 1999-12-31 | CN¥220.90 Million ≈ $32.33 Million |
+4.48% |
| 1998-12-31 | CN¥211.44 Million ≈ $30.94 Million |
+13.93% |
| 1997-12-31 | CN¥185.58 Million ≈ $27.16 Million |
+150.97% |
| 1996-12-31 | CN¥73.95 Million ≈ $10.82 Million |
+79.71% |
| 1995-12-31 | CN¥41.15 Million ≈ $6.02 Million |
+5.42% |
| 1994-12-31 | CN¥39.03 Million ≈ $5.71 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Berry Genomics Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 6454237700.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥64.54 Million | 3.84% |
| Common Stock | CN¥353.52 Million | 21.05% |
| Other Comprehensive Income | CN¥439.84 Million | 26.19% |
| Other Components | CN¥821.57 Million | 48.92% |
| Total Equity | CN¥1.68 Billion | 100.00% |
Berry Genomics Co Ltd Competitors by Market Cap
The table below lists competitors of Berry Genomics Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Turaco Gold Ltd
AU:TCG
|
$406.66 Million |
|
Ningbo David Medical Device Co Ltd
SHE:300314
|
$406.68 Million |
|
Xin Hee Co Ltd
SHE:003016
|
$406.75 Million |
|
Good Finance Securities Co Ltd
TWO:6021
|
$406.76 Million |
|
Citra Putra Realty Tbk PT
JK:CLAY
|
$406.60 Million |
|
LF Corp
KO:093050
|
$406.60 Million |
|
Shanghai Xujiahui Commercial Co Ltd
SHE:002561
|
$406.41 Million |
|
Zhangjiagang Zhonghuan Hailu High-End Equipment Co. Ltd.
SHE:301040
|
$406.37 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Berry Genomics Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,864,035,046 to 1,679,476,362, a change of -184,558,684 (-9.9%).
- Net loss of 192,428,499 reduced equity.
- Dividend payments of 8,692,207 reduced retained earnings.
- Other comprehensive income increased equity by 423,341,786.
- Other factors decreased equity by 406,779,764.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-192.43 Million | -11.46% |
| Dividends Paid | CN¥8.69 Million | -0.52% |
| Other Comprehensive Income | CN¥423.34 Million | +25.21% |
| Other Changes | CN¥-406.78 Million | -24.22% |
| Total Change | CN¥- | -9.90% |
Book Value vs Market Value Analysis
This analysis compares Berry Genomics Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.65x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 30.37x to 1.65x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1994-12-31 | CN¥0.26 | CN¥7.86 | x |
| 1995-12-31 | CN¥0.27 | CN¥7.86 | x |
| 1996-12-31 | CN¥0.46 | CN¥7.86 | x |
| 1997-12-31 | CN¥1.21 | CN¥7.86 | x |
| 1998-12-31 | CN¥1.38 | CN¥7.86 | x |
| 1999-12-31 | CN¥1.44 | CN¥7.86 | x |
| 2000-12-31 | CN¥1.35 | CN¥7.86 | x |
| 2001-12-31 | CN¥1.06 | CN¥7.86 | x |
| 2002-12-31 | CN¥0.72 | CN¥7.86 | x |
| 2003-12-31 | CN¥0.74 | CN¥7.86 | x |
| 2004-12-31 | CN¥0.75 | CN¥7.86 | x |
| 2005-12-31 | CN¥0.65 | CN¥7.86 | x |
| 2006-12-31 | CN¥0.66 | CN¥7.86 | x |
| 2007-12-31 | CN¥0.62 | CN¥7.86 | x |
| 2008-12-31 | CN¥0.64 | CN¥7.86 | x |
| 2009-12-31 | CN¥0.71 | CN¥7.86 | x |
| 2010-12-31 | CN¥0.77 | CN¥7.86 | x |
| 2011-12-31 | CN¥0.77 | CN¥7.86 | x |
| 2012-12-31 | CN¥0.78 | CN¥7.86 | x |
| 2013-12-31 | CN¥0.76 | CN¥7.86 | x |
| 2014-12-31 | CN¥0.86 | CN¥7.86 | x |
| 2015-12-31 | CN¥0.78 | CN¥7.86 | x |
| 2016-12-31 | CN¥0.57 | CN¥7.86 | x |
| 2017-12-31 | CN¥6.07 | CN¥7.86 | x |
| 2018-12-31 | CN¥5.40 | CN¥7.86 | x |
| 2019-12-31 | CN¥6.57 | CN¥7.86 | x |
| 2020-12-31 | CN¥6.81 | CN¥7.86 | x |
| 2021-12-31 | CN¥7.04 | CN¥7.86 | x |
| 2022-12-31 | CN¥6.51 | CN¥7.86 | x |
| 2023-12-31 | CN¥5.28 | CN¥7.86 | x |
| 2024-12-31 | CN¥4.75 | CN¥7.86 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Berry Genomics Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -11.46%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -17.85%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 1.42x
- Recent ROE (-11.46%) is below the historical average (1.14%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1994 | 31.52% | 16.15% | 0.76x | 2.57x | CN¥8.40 Million |
| 1995 | 36.01% | 13.84% | 0.78x | 3.32x | CN¥10.70 Million |
| 1996 | 22.62% | 13.98% | 0.57x | 2.86x | CN¥8.80 Million |
| 1997 | 13.84% | 22.28% | 0.39x | 1.59x | CN¥6.99 Million |
| 1998 | 11.37% | 19.95% | 0.38x | 1.48x | CN¥2.84 Million |
| 1999 | 6.33% | 13.78% | 0.33x | 1.37x | CN¥-7.98 Million |
| 2000 | 0.79% | 2.03% | 0.24x | 1.63x | CN¥-18.74 Million |
| 2001 | -27.84% | -86.72% | 0.14x | 2.24x | CN¥-60.27 Million |
| 2002 | -46.67% | -81.14% | 0.26x | 2.22x | CN¥-61.70 Million |
| 2003 | 2.83% | 3.90% | 0.31x | 2.30x | CN¥-8.04 Million |
| 2004 | 0.57% | 0.53% | 0.43x | 2.47x | CN¥-10.64 Million |
| 2005 | -14.48% | -10.93% | 0.56x | 2.37x | CN¥-24.14 Million |
| 2006 | 1.20% | 0.80% | 0.61x | 2.45x | CN¥-8.79 Million |
| 2007 | -13.43% | -7.03% | 0.80x | 2.39x | CN¥-22.14 Million |
| 2008 | 2.89% | 0.98% | 0.92x | 3.19x | CN¥-6.93 Million |
| 2009 | 9.68% | 2.56% | 1.12x | 3.39x | CN¥-344.99K |
| 2010 | 6.95% | 1.74% | 1.21x | 3.30x | CN¥-3.54 Million |
| 2011 | 0.43% | 0.12% | 1.15x | 3.04x | CN¥-11.17 Million |
| 2012 | 0.33% | 0.12% | 0.97x | 2.89x | CN¥-11.41 Million |
| 2013 | -5.33% | -2.35% | 0.64x | 3.55x | CN¥-17.70 Million |
| 2014 | 5.29% | 2.51% | 0.61x | 3.43x | CN¥-6.12 Million |
| 2015 | -11.05% | -5.65% | 0.46x | 4.24x | CN¥-24.78 Million |
| 2016 | -3.67% | -1.69% | 0.45x | 4.80x | CN¥-15.59 Million |
| 2017 | 15.15% | 19.87% | 0.65x | 1.18x | CN¥79.09 Million |
| 2018 | 14.08% | 18.62% | 0.66x | 1.14x | CN¥77.75 Million |
| 2019 | 16.78% | 24.15% | 0.53x | 1.32x | CN¥157.78 Million |
| 2020 | 8.82% | 13.68% | 0.47x | 1.36x | CN¥-28.18 Million |
| 2021 | -4.41% | -7.72% | 0.40x | 1.41x | CN¥-358.88 Million |
| 2022 | -10.96% | -18.44% | 0.43x | 1.39x | CN¥-482.39 Million |
| 2023 | -22.92% | -37.10% | 0.42x | 1.47x | CN¥-613.60 Million |
| 2024 | -11.46% | -17.85% | 0.45x | 1.42x | CN¥-360.38 Million |
Industry Comparison
This section compares Berry Genomics Co Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $1,748,944,723
- Average return on equity (ROE) among peers: 21.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Berry Genomics Co Ltd (000710) | CN¥1.65 Billion | 31.52% | 0.42x | $406.61 Million |
| Zhejiang DiAn Diagnostics Co (300244) | $110.32 Million | 15.56% | 0.62x | $1.67 Billion |
| Hangzhou Tigermed Consulting (300347) | $146.03 Million | 32.73% | 0.28x | $4.33 Billion |
| Beijing Strong Biotechnologies Inc (300406) | $385.67 Million | 35.53% | 0.12x | $972.92 Million |
| Ningbo MedicalSystem Biotechnology Co Ltd (300439) | $2.93 Billion | 8.79% | 0.26x | $470.71 Million |
| Maccura Biotechnology Co Ltd (300463) | $6.53 Billion | 10.85% | 0.25x | $742.36 Million |
| Guangdong Hybribio Biotech Co Ltd (300639) | $2.53 Billion | 14.31% | 0.13x | $505.18 Million |
| BGI Genomics Co Ltd (300676) | $150.37 Million | 54.36% | 5.67x | $2.17 Billion |
| Amoy Diagnostics Co Ltd (300685) | $1.70 Billion | 15.35% | 0.14x | $959.68 Million |
| Shanghai Labway Clinical Laboratory Co Ltd (301060) | $1.25 Billion | 8.85% | 0.18x | $507.55 Million |
About Berry Genomics Co Ltd
Berry Genomics Co.,Ltd, a genomics and life science company, develops and commercializes of genetic test technologies in clinical applications in China. The company offers non-invasive DNA prenatal testing service, genetic disease testing, tumor genetic testing, NextSeq CN500 gene sequencer, and laboratory solutions. It also provides technology services, such as human genome sequencing, transcri… Read more